| Literature DB >> 35566212 |
János Marton1, Anikó Fekete2, Paul Cumming3,4, Sándor Hosztafi5, Pál Mikecz2, Gjermund Henriksen6,7,8.
Abstract
6,14-ethenomorphinans are semisynthetic opiate derivatives containing an ethylene bridge between positions 6 and 14 in ring-C of the morphine skeleton that imparts a rigid molecular structure. These compounds represent an important family of opioid receptor ligands in which the 6,14-etheno bridged structural motif originates from a [4 + 2] cycloaddition of morphinan-6,8-dienes with dienophiles. Certain 6,14-ethenomorphinans having extremely high affinity for opioid receptors are often non-selective for opioid receptor subtypes, but this view is now undergoing some revision. The agonist 20R-etorphine and 20R-dihydroetorphine are several thousand times more potent analgesics than morphine, whereas diprenorphine is a high-affinity non-selective antagonist. The partial agonist buprenorphine is used as an analgesic in the management of post-operative pain or in substitution therapy for opiate addiction, sometimes in combination with the non-selective antagonist naloxone. In the context of the current opioid crisis, we communicated a summary of several decades of work toward generating opioid analgesics with lesser side effects or abuse potential. Our summary placed a focus on Diels-Alder reactions of morphinan-6,8-dienes and subsequent transformations of the cycloadducts. We also summarized the pharmacological aspects of radiolabeled 6,14-ethenomorphinans used in molecular imaging of opioid receptors.Entities:
Keywords: Diels–Alder reaction; Grignard addition; O-demethylation; morphinan-6,8-dienes; morphine alkaloids; opioid receptors; positron emission tomography; radiolabeling
Mesh:
Substances:
Year: 2022 PMID: 35566212 PMCID: PMC9102320 DOI: 10.3390/molecules27092863
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927